Listed by the USPTO as OH, TAYLOR V
Tech Center 1600 • Art Units: 1622 1624 1625 1629
This examiner grants 81% of resolved cases
OH, TAYLOR V has resolved 1782 cases in Tech Center 1600 and Art Unit 1622. The allowance rate is 81.3%, the interview lift is 15.3%, and the median time to allowance is 825 days. The large resolved docket makes the allowance figure a useful basis for planning, while the positive interview lift supports considering interviews without making them the sole focus of prosecution strategy.
The principal companies are Kuleon LLC, The Brigham and Women's Hospital Inc., and Zydus Lifesciences Limited. The leading firms are COOLEY LLP, FOLEY HOAG, LLP (General), and GOODWIN PROCTER LLP. The profile combines a high allowance rate with a median timing of 825 days, giving counsel practical reference points for applications in Art Unit 1622.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18860397 | PROCESS FOR THE PREPARATION OF [1,4,5]-OXADIAZEPINE DERIVATIVES | Non-Final OA | Syngenta Crop Protection AG |
| 18247057 | Selective Agonists of 5-HT2A Receptor and Methods of Use | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18922313 | ANACARDIC ACID FOR INFLAMMATORY CONDITIONS | Non-Final OA | Vanderbilt University |
| 18832446 | THERAPEUTIC AGENT FOR CANCER | Non-Final OA | TOHOKU UNIVERSITY |
| 18792715 | Synthesis of MEK7 Inhibitors and methods of Use Thereof | Non-Final OA | Northwestern University |
| 18687993 | TOPICAL DRUG TREATMENT TO PREVENT OR REDUCE CORNEAL SCARRING | Non-Final OA | The Cleveland Clinic Foundation |
| 18832887 | SYNTHESIS OF A KIF18A INHIBITOR | Non-Final OA | Amgen Inc. |
| 18811575 | PHOSPHONIUM-BEARING CONJUGATED POLYELECTROLYTES | Non-Final OA | Board of Regents, The University of Texas System |
| 18262256 | USES OF MELANOCORTIN-4 RECEPTOR AGONIST | Final Rejection | LG CHEM, LTD. |
| 18850267 | ASCORBIC ACID DERIVATIVE OR SALT THEREOF, ADDITIVE FOR POLYMERIZATION INITIATION, POLYMERIZATION INITIATOR, CURABLE COMPOSITION PREPARATION KIT, CURABLE COMPOSITION, CURED PRODUCT, AND DENTAL MATERIAL | Non-Final OA | MITSUI CHEMICALS, INC. |
| 18833602 | CYCLIC(ALKYL)(AMINO)ALKOXY-SUBSTITUTED ARYL-PYRONE COMPOUND AND USE THEREOF | Non-Final OA | INSTITUTE OF CHINESE MATERIA MEDICA, CHINA ACADEMY OF CHINESE MEDICAL SCIENCES |
| 18863744 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | Non-Final OA | Janssen Pharmaceutica NV |
| 18631587 | Monohydrate Salt of Denatonium Acetate | Final Rejection | AARDVARK THERAPEUTICS, INC. |
| 18850218 | P2X3 INHIBITOR COMPOUND, SALT THEREOF, POLYMORPH THEREOF AND USE THEREOF | Non-Final OA | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy81.3% of resolved applications examined by Taylor V Oh were allowed (1,782 resolved cases), compared with 60.6% across Art Unit 1622 over the last five years.
This examiner's interview lift is +15.3 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Taylor V Oh took 825 days on average from filing to allowance.
Taylor V Oh examines applications in Art Unit 1622 in Tech Center 1600 (Biotechnology & Pharmaceuticals).
